SCHEMBL2264740

SCHEMBL2264740

CC(N)(Cc1cnc[nH]1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ARG1 P05089 1/20 0.53
ARG2 P78540 1/20 0.53
FDPS P14324 1/20 0.53
ALDH1A1 P00352 3/20 0.51
CYP3A4 P08684 2/20 0.51
NFKB1 P19838 2/20 0.51
TSHR P16473 2/20 0.51
GABRA1 P14867 1/20 0.51
GABRR1 P24046 1/20 0.51
GABRR2 P28476 1/20 0.51
GABRA5 P31644 1/20 0.51
GABRB2 P47870 1/20 0.51
GABRA4 P48169 1/20 0.51
HRH4 Q9H3N8 5/20 0.50
HRH3 Q9Y5N1 5/20 0.50
KDM4E B2RXH2 2/20 0.50
PMP22 Q01453 2/20 0.50
MAPT P10636 1/20 0.50
SLC7A5 Q01650 1/20 0.49
CPB2 Q96IY4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2264734 1.00 ARG1 (0.53) ARG1ARG2FDPSALDH1A1CYP3A4
SCHEMBL3510790 0.82 ALDH1A1 (0.59) ARG1ARG2FDPSALDH1A1CYP3A4
SCHEMBL5692256 0.81 FDPS (0.54) ARG1ARG2FDPSALDH1A1CYP3A4
SCHEMBL20644246 0.80 HRH4 (0.57) ARG1ARG2FDPSALDH1A1CYP3A4
SCHEMBL11611208 0.78 ARG1 (0.51) ARG1ARG2FDPSALDH1A1CYP3A4
SCHEMBL11154182 0.78 ARG1 (0.61) ARG1ARG2FDPSALDH1A1CYP3A4
SCHEMBL11159616 0.78 ARG1 (0.61) ARG1ARG2FDPSALDH1A1CYP3A4
SCHEMBL11615111 0.76 ARG1 (0.50) ARG1ARG2FDPSALDH1A1CYP3A4
SCHEMBL11169995 0.76 HRH4 (0.50) ARG1ARG2FDPSALDH1A1CYP3A4
Hydrochloric Acid SCHEMBL11626458 0.75 ARG1 (0.49) ARG1ARG2FDPSALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8445440-B2 Dimeric IAP inhibitors NOVARTIS AG (CH) 2013-05-21 US disclosed
US-20110206690-A1 DIMERIC IAP INHIBITORS NOVARTIS AG (CH) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110206690-A1 DIMERIC IAP INHIBITORS XIAP, BIRC5, BIRC2 ARG1 3683/4885ARG2 3473/4885FDPS 3123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.